- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Jindalee Lithium
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Nascent Biotech (OTC:NBIO), a clinical-stage biotech company which works to develop monoclonal antibodies for cancer treatment, raised $2.1 million to develop their lead product, Pritumumab.
Nascent Biotech (OTC:NBIO), a clinical-stage biotech company which works to develop monoclonal antibodies for cancer treatment, raised $2.1 million to develop their lead product, Pritumumab.
According to a press release:
Pritumumab is a fully human monoclonal antibody being developed initially for the treatment of malignant and non malignant Gliomas.
One of the biggest challenges in the development of any antibody product is to show that it can be manufactured, at appropriate scale, to clinical grade and in sufficient quantity for human trials. We have attained this goal and manufactured more than enough product to complete our initial Phase 1/Phase 2 human trials on Brain Cancers, with more than adequate amounts left over to initiate trials in other epithelial cancers such as breast, lung, colon and pancreas. Pritumumab is unique in its ability to react strongly with all these major malignancies.
An additional challenge is to understand the toxicity profile. We have completed a toxicology study, in compliance with FDA guidance, and we have demonstrated no in life toxicities in the two species studied (Monkey and Rat).
Another significant milestone worth noting is that the FDA granted Nascent Biotech an Orphan Drug Designation for Gliomas (brain cancer).
Click here to read the full press release from Nascent Biotech.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.